NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024

[Pelican Press 0]

This is the hidden content, please

• Sign In
• or
• Sign Up

NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024

NextCure, Inc. (NASDAQ:NXTC) and LigaChem Biosciences, Inc. are set to present new clinical data on their novel ******* therapy, LNCB74, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 2, 2025. LNCB74 is a first-in-human, B7-H4 targeted antibody-drug conjugate (ADC) currently being evaluated in a Phase 1 trial for patients with advanced solid tumors, including platinum-resistant ovarian, treatment-refractory breast, endometrial, biliary tract, and squamous non-small cell lung cancers.

NextCure, Inc. (NXTC)’s B7-H4 ADC LNCB74 Enters Phase 1 Dose Escalation

A scientist in a lab researching the biology of a ******* cell.

The ongoing study is in the dose escalation phase and will also include randomized dose expansion and optimization, with an emphasis on safety and biomarker analysis. B7-H4, the ADC’s target, is highly expressed in several tumor types but limited in normal tissues, making it an appealing candidate for targeted therapy.

According to NextCure, Inc. (NASDAQ:NXTC)’s Chief Medical Officer, Dr. Udayan Guha, LNCB74 has shown a superior safety profile and potent anti-tumor activity in preclinical models. The poster, abstract TPS3167, will be featured during the “Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology” session.

NXTC closed nearly 6% higher on May 29.

While we acknowledge the potential of NXTC to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than NXTC and that has 100x upside potential, check out our report about this

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up

READ NEXT: 

This is the hidden content, please

• Sign In
• or
• Sign Up

 and 

This is the hidden content, please

• Sign In
• or
• Sign Up

Disclosure: None.

This is the hidden content, please

• Sign In
• or
• Sign Up

#NextCure #NXTC #LCB #Unveil #Promising #Preclinical #Data #B7H4 #ADC #AACR

This is the hidden content, please

• Sign In
• or
• Sign Up

This is the hidden content, please

• Sign In
• or
• Sign Up

For verified travel tips and real support, visit: https://hopzone.eu/